Literature DB >> 7909819

Visualization of the thyrotropin receptor on the cell surface by potent autoantibodies.

R de Forteza1, C U Smith, J Amin, J M McKenzie, M Zakarija.   

Abstract

In autoimmune thyroid disease there are various autoantibodies (Ab) to thyroid cell components. Among the best characterized are those to thyroid peroxidase (TPOAb) and to the thyrotropin receptor (TRAb). While TPOAb were successfully used to visualize TPO in human thyroid cells (HTC) and a rat thyroid cell line (FRTL5) by indirect immunofluorescence (IFL), similar attempts with TRAb and thyrotropin receptor (TSHR) failed. This could have been due to either relatively low serum levels of TRAb and/or low number of TSHR on thyroid cells. To test these hypotheses, we estimated the number of TSH binding sites on HTC, FRTL5 and Chinese hamster ovary (CHO) cells, transfected with cloned human TSHR (JP-26 cells), and for IFL staining employed 3 sera with the highest potency TRAb in our possession. A clear granular surface staining was detected on all 3 cell types with two sera; with the third, the least potent, no staining was seen. The density of staining paralleled the estimated number of TSHR per cell, i.e., JP-26 > FRTL5 > HTC. TSHR was also visualized on transiently transfected cells (COS-7-TSHR), facilitating quantitation of transfection. Our results suggest that the limiting factor in direct visualization of the TSHR is the TRAb concentration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909819     DOI: 10.1210/jcem.78.5.7909819

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Cytokines, IgG subclasses and costimulation in a mouse model of thyroid autoimmunity induced by injection of fibroblasts co-expressing MHC class II and thyroid autoantigens.

Authors:  X M Yan; J Guo; P Pichurin; K Tanaka; J C Jaume; B Rapoport; S M McLachlan
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  Clonal relationships between thyroid-stimulating hormone receptor-stimulating antibodies illustrate the effect of hypermutation on antibody function.

Authors:  Carolyn J Padoa; Sanne L Larsen; Christiane S Hampe; Jacqueline A Gilbert; Elif Dagdan; Laszlo Hegedus; Deborah Dunn-Walters; J Paul Banga
Journal:  Immunology       Date:  2009-10-21       Impact factor: 7.397

Review 3.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

4.  Role of self-tolerance and chronic stimulation in the long-term persistence of adenovirus-induced thyrotropin receptor antibodies in wild-type and transgenic mice.

Authors:  Sandra M McLachlan; Holly A Aliesky; Chun-Rong Chen; Basil Rapoport
Journal:  Thyroid       Date:  2012-07-24       Impact factor: 6.568

5.  Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor.

Authors:  Gregorio D Chazenbalk; Pavel Pichurin; Chun-Rong Chen; Francesco Latrofa; Alan P Johnstone; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 6.  Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

7.  Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves' disease.

Authors:  Yumiko Mizutori; Chun-Rong Chen; Francesco Latrofa; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Endocrinol Metab       Date:  2008-12-09       Impact factor: 5.958

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.